Compounds > lapatinib
Page last updated: 2024-09-05

lapatinib and Triple Negative Breast Neoplasms

lapatinib has been researched along with Triple Negative Breast Neoplasms in 31 studies

Research

Studies (31)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's22 (70.97)24.3611
2020's9 (29.03)2.80

Authors

AuthorsStudies
Chen, Y; Hin Cho, C; Imani, S; Jabbarzadeh Kaboli, P; Jomhori, M; Li, M; Luo, S; Shen, J; Wu, X; Wu, Z; Xiang, S; Xiao, Z; Zhao, Y1
Cheng, N; Ding, D; Jiang, M; Li, W; Lou, H; Miao, Y; Sheng, H; Wu, X; Zhang, W; Zhao, L1
Al-Zubaidi, Y; Bourget, K; Murray, M; Rahman, MK; Tam, S; Zhou, F1
Chen, L; Chen, YF; Ge, JY; Liu, CC; Ma, D; Shao, ZM; Yu, KD; Zhu, SY1
Chintalaramulu, N; Cock, IE; Nguyen, NT; Vadivelu, R1
Fan, Y; Guo, Z; Liang, J; Ma, M; Sui, J; Sun, Y; Xu, Z; Yang, Y; Zhang, X; Zhao, M1
Chen, C; Ding, W; Duan, D; Hsieh, YC; Huang, M; Kong, Y; Li, F; Puno, P; Xiao, W; Yang, C; Zhang, R; Zhou, Y; Zhou, Z1
Acosta, EP; Caterinicchia, V; Chen, D; Della Manna, DL; Falkson, CI; Forero-Torres, A; Li, Y; May, JE; Nabell, LM; Olariu, E; Rocque, GB; Stringer-Reasor, EM; Vaklavas, C; Yang, ES1
Cao, J; Du, Y; Hu, X; Li, T; Liu, X; Tao, Z; Wang, B; Wang, L; Zhang, J; Zhu, Y1
Chanrion, M; Dewson, G; Geneste, O; Giner, G; Gong, JN; Gräsel, J; Herold, MJ; Huang, DCS; Lalaoui, N; Lessene, G; Li, X; Lindeman, GJ; Liu, K; Maragno, AL; Merino, D; Pal, B; Schneider, E; Segal, D; Serrano, A; Smyth, GK; Vaillant, F; Visvader, JE; Whittle, JR1
Engelke, LH; Gohr, K; Hamacher, A; Kassack, MU1
Agrawal, S; Ahmad, H; Arya, A; Chadchan, SB; Dwivedi, AK; Dwivedi, M; Jha, RK; Kaushik, S; Mitra, K; Sikandar, R1
Brantley-Sieders, DM; Cook, RS; Dimobi, SC; Duvall, CL; Ericsson, PG; Hicks, DJ; Jackson, MA; Joly, MM; Kavanaugh, TE; Kilchrist, KV; Lee, LH; Sanchez, V; Sarett, SM; Wang, S; Werfel, TA1
Cho, HJ; Lee, SY1
Goodwin, JS; Korolkova, OY; Ochieng, J; Sakwe, AM; Whalen, DS; Widatalla, SE; Williams, KP1
Abo-Elfadl, MT; Abo-Zeid, MAM; Gamal-Eldeen, AM1
Guldner, IH; Host, M; Howe, EN; Jiang, L; Koenig, JK; Littlepage, LE; Nakshatri, H; Ni, Y; Schmidt, KR; Schnepp, PM; Sun, L; Tan, X; Werner, BA; Wu, J; Zhang, S1
Chen, CH; Chen, JY; Chen, WS; Chen, YJ; Chien, PH; Hsia, TC; Huang, WC; Liu, SH; Shih, CY; Tu, CY; Wei, YL; Yeh, MH; Yu, MC; Yu, YL1
Ali, SM; Alpaugh, RK; Buell, JK; Cristofanilli, M; Downing, SR; Lipson, D; Miller, VA; Palmer, GA; Ross, JS; Stephens, PJ; Wu, H; Yu, JQ1
Chen, CH; Chen, WS; Chen, YJ; Hsia, TC; Hsu, KW; Hsu, MH; Huang, WC; Liu, LC; Tu, CY; Wei, YL; Yeh, MH; Yu, MC1
Arima, Y; Hosonaga, M; Kohno, N; Saya, H; Sugihara, E1
Baumann, C; Gusenbauer, S; Kéri, G; Őrfi, L; Pénzes, K; Szabadkai, I; Torka, R; Ullrich, A1
Jing, T; Pang, X; Wan, X; Xu, W; Zhang, Q; Zhang, Z; Zheng, X1
Piccart, M; Sonnenblick, A1
Ethier, SP; Soloff, AC; Williams, CB; Yeh, ES1
Chen, YJ; Hsiao, YC; Huang, WC; Liu, JF; Tang, CH; Yeh, MH1
Chen, KF; Chen, MH; Chen, YT; Chu, PY; Hsu, CC; Hsu, CJ; Hu, MH; Huang, CT; Lee, CH; Liu, CY; Shiau, CW; Tsai, WC; Tseng, LM; Wang, DS1
Jiang, T; Jiang, X; Pang, X; Pang, Z; Wan, X; Xu, W; Zhang, Q; Zhang, Z; Zhao, J; Zheng, X1
Denkert, C; Diebold, K; Eidtmann, H; Fasching, PA; Glados, M; Habeck, JO; Heck, E; Holms, F; Ingold Heppner, B; Krabisch, P; Lederer, B; Loibl, S; Lorenz, P; Ober, A; Pfitzner, BM; Rezai, M; Schmitt, W; Solbach, C; Tesch, H; Untch, M; Zahm, DM1
Gonçalves, A1
Blohmer, JU; Darb-Esfahani, S; Denkert, C; Dietel, M; Endris, V; Jackisch, C; Klare, P; Kümmel, S; Loi, S; Loibl, S; Möbs, M; Nekljudova, V; Reimer, T; Salat, C; Schem, C; Schmitt, W; Sinn, B; Sinn, P; Stenzinger, A; Tesch, H; Untch, M; von Minckwitz, G; Weichert, W1

Reviews

3 review(s) available for lapatinib and Triple Negative Breast Neoplasms

ArticleYear
Adjuvant systemic therapy in breast cancer: quo vadis?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:8

    Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Mastectomy; Paclitaxel; Patient Selection; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Tamoxifen; Trastuzumab; Triple Negative Breast Neoplasms

2015
Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
    Advances in cancer research, 2015, Volume: 127

    Topics: Antineoplastic Agents; Biomarkers, Tumor; ErbB Receptors; Female; Humans; Lapatinib; Ligands; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab; Triple Negative Breast Neoplasms

2015
[Not Available].
    Bulletin du cancer, 2016, Volume: 103, Issue:6 Suppl 1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Neoadjuvant Therapy; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triple Negative Breast Neoplasms

2016

Trials

2 trial(s) available for lapatinib and Triple Negative Breast Neoplasms

ArticleYear
An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.
    Breast cancer research : BCR, 2021, 03-04, Volume: 23, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Disease Management; Drug Monitoring; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pilot Projects; Treatment Outcome; Triple Negative Breast Neoplasms

2021
Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Dec-01, Volume: 22, Issue:23

    Topics: Biomarkers, Tumor; Disease-Free Survival; Female; Humans; Lapatinib; Lymphocytes; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoadjuvant Therapy; Prognosis; Prospective Studies; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triple Negative Breast Neoplasms

2016

Other Studies

26 other study(ies) available for lapatinib and Triple Negative Breast Neoplasms

ArticleYear
Pharmacotranscriptomic profiling of resistant triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K/Akt signaling under cytotoxic stress.
    Gene, 2022, Mar-30, Volume: 816

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Berberine; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase 6; DNA (Cytosine-5-)-Methyltransferase 1; Epigenesis, Genetic; ErbB Receptors; Gene Expression Regulation, Neoplastic; Genes, myc; Humans; Lapatinib; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Pyrimidines; Pyrroles; Signal Transduction; Transcriptome; Triple Negative Breast Neoplasms; Up-Regulation

2022
Co-loaded lapatinib/PAB by ferritin nanoparticles eliminated ECM-detached cluster cells via modulating EGFR in triple-negative breast cancer.
    Cell death & disease, 2022, 06-20, Volume: 13, Issue:6

    Topics: Cell Line, Tumor; Diterpenes; ErbB Receptors; Ferritins; Humans; Lapatinib; Nanoparticles; Neoplasm Recurrence, Local; Triple Negative Breast Neoplasms

2022
The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells.
    Pharmacological reports : PR, 2022, Volume: 74, Issue:5

    Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cytotoxins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Triple Negative Breast Neoplasms

2022
Multiomics of HER2-low triple-negative breast cancer identifies a receptor tyrosine kinase-relevant subgroup with therapeutic prospects.
    JCI insight, 2023, Nov-22, Volume: 8, Issue:22

    Topics: Humans; Lapatinib; Multiomics; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Signal Transduction; Triple Negative Breast Neoplasms

2023
Lapatinib inhibits doxorubicin induced migration of HER2-positive breast cancer cells.
    Inflammopharmacology, 2020, Volume: 28, Issue:5

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Movement; Cell Survival; Doxorubicin; ErbB Receptors; Female; Fibroblasts; Humans; Lapatinib; Protein Kinase Inhibitors; Receptor, ErbB-2; Triple Negative Breast Neoplasms

2020
Acid-labile polysaccharide prodrug via lapatinib-sensitizing effect substantially prevented metastasis and postoperative recurrence of triple-negative breast cancer.
    Nanoscale, 2020, Jul-02, Volume: 12, Issue:25

    Topics: Animals; Cell Line, Tumor; Doxorubicin; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Nanoparticles; Prodrugs; Tissue Distribution; Triple Negative Breast Neoplasms

2020
Targeting ubiquitin conjugating enzyme UbcH5b by a triterpenoid PC3-15 from Schisandra plants sensitizes triple-negative breast cancer cells to lapatinib.
    Cancer letters, 2021, 04-28, Volume: 504

    Topics: Animals; Antineoplastic Agents; Humans; Lapatinib; Mice; Schisandra; Structure-Activity Relationship; Survival Analysis; Triple Negative Breast Neoplasms; Triterpenes; Ubiquitin-Conjugating Enzymes; Ubiquitination; Xenograft Model Antitumor Assays

2021
Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer.
    Cell death & disease, 2021, 07-08, Volume: 12, Issue:7

    Topics: Annexin A6; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Exosomes; Gemcitabine; Humans; Lapatinib; Proteolysis; Triple Negative Breast Neoplasms; Ubiquitination

2021
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.
    Science translational medicine, 2017, Aug-02, Volume: 9, Issue:401

    Topics: Animals; bcl-2 Homologous Antagonist-Killer Protein; bcl-X Protein; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Amplification; Humans; Lapatinib; Myeloid Cell Leukemia Sequence 1 Protein; Pyrimidines; Quinazolines; Receptor, ErbB-2; Survival Analysis; Taxoids; Thiophenes; Trastuzumab; Treatment Outcome; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2017
Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    BMC cancer, 2017, Nov-03, Volume: 17, Issue:1

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Lapatinib; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms

2017
CD44 targeting hyaluronic acid coated lapatinib nanocrystals foster the efficacy against triple-negative breast cancer.
    Nanomedicine : nanotechnology, biology, and medicine, 2018, Volume: 14, Issue:2

    Topics: Animals; Antineoplastic Agents; Female; Hyaluronan Receptors; Hyaluronic Acid; Lapatinib; Mice; Mice, Inbred BALB C; Nanoparticles; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2018
Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival.
    Cancer research, 2018, 04-01, Volume: 78, Issue:7

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Disease Models, Animal; Female; Humans; Lapatinib; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Protein Kinase Inhibitors; Rapamycin-Insensitive Companion of mTOR Protein; Receptor, ErbB-2; RNA, Small Interfering; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2018
Mitochondria Targeting and Destabilizing Hyaluronic Acid Derivative-Based Nanoparticles for the Delivery of Lapatinib to Triple-Negative Breast Cancer.
    Biomacromolecules, 2019, 02-11, Volume: 20, Issue:2

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Humans; Hyaluronic Acid; Lapatinib; Mammary Neoplasms, Experimental; Mice; Mitochondria; Nanoparticles; Triple Negative Breast Neoplasms

2019
Lapatinib-induced annexin A6 upregulation as an adaptive response of triple-negative breast cancer cells to EGFR tyrosine kinase inhibitors.
    Carcinogenesis, 2019, 08-22, Volume: 40, Issue:8

    Topics: Annexin A6; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction; Transcriptional Activation; Triple Negative Breast Neoplasms

2019
Evaluation of lapatinib cytotoxicity and genotoxicity on MDA-MB-231 breast cancer cell line.
    Environmental toxicology and pharmacology, 2019, Volume: 71

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; DNA Damage; Dose-Response Relationship, Drug; ErbB Receptors; Humans; Inhibitory Concentration 50; Lapatinib; Micronuclei, Chromosome-Defective; Time Factors; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53

2019
Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer.
    Nature communications, 2019, 06-28, Volume: 10, Issue:1

    Topics: Antineoplastic Agents; Cell Cycle; Death Domain Receptor Signaling Adaptor Proteins; DNA-Binding Proteins; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Receptor, ErbB-2; Retinoblastoma Protein; Triple Negative Breast Neoplasms

2019
Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors.
    Breast cancer research : BCR, 2013, Nov-12, Volume: 15, Issue:6

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; I-kappa B Kinase; Lapatinib; Mice, SCID; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2013
Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Sep-01, Volume: 32, Issue:25

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal, Breast; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Triple Negative Breast Neoplasms

2014
Trichostatin A suppresses EGFR expression through induction of microRNA-7 in an HDAC-independent manner in lapatinib-treated cells.
    BioMed research international, 2014, Volume: 2014

    Topics: Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Humans; Hydroxamic Acids; Lapatinib; MicroRNAs; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Triple Negative Breast Neoplasms

2014
Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells.
    Cancer science, 2014, Volume: 105, Issue:7

    Topics: Animals; Breast Neoplasms; CD24 Antigen; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lapatinib; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2014
Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
    Neoplasia (New York, N.Y.), 2014, Volume: 16, Issue:4

    Topics: Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Cell Line; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; GPI-Linked Proteins; Humans; Lapatinib; Ligands; Mice; Myelin Proteins; Neoplasms; Nogo Receptor 1; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Protein Multimerization; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Cell Surface; Transcription, Genetic; Transcriptional Activation; Triple Negative Breast Neoplasms

2014
The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.
    International journal of pharmaceutics, 2015, Apr-30, Volume: 484, Issue:1-2

    Topics: Animals; Antineoplastic Agents; Female; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Quinazolines; Serum Albumin; Treatment Outcome; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2015
Lapatinib increases motility of triple-negative breast cancer cells by decreasing miRNA-7 and inducing Raf-1/MAPK-dependent interleukin-6.
    Oncotarget, 2015, Nov-10, Volume: 6, Issue:35

    Topics: Antineoplastic Agents; Blotting, Western; Cell Movement; Cell Proliferation; Chromatin Immunoprecipitation; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Immunoprecipitation; Interleukin-6; Lapatinib; MicroRNAs; Mitogen-Activated Protein Kinase 1; Phosphorylation; Proto-Oncogene Proteins c-raf; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Triple Negative Breast Neoplasms; Tumor Cells, Cultured

2015
Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.
    Oncotarget, 2016, Feb-23, Volume: 7, Issue:8

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autoantigens; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Humans; Lapatinib; MCF-7 Cells; Membrane Proteins; Mice; Mice, Nude; Promoter Regions, Genetic; Protein Kinase Inhibitors; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2016
Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain.
    Oncotarget, 2016, Jun-07, Volume: 7, Issue:23

    Topics: Administration, Intravenous; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Drug Carriers; Drug Compounding; Drug Stability; Female; Lapatinib; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasm Invasiveness; Phosphatidylcholines; Protein Kinase Inhibitors; Quinazolines; Serum Albumin, Human; Tissue Distribution; Triple Negative Breast Neoplasms

2016
Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Oncotarget, 2016, 10-18, Volume: 7, Issue:42

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Mutation; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53

2016